Association of Transforming Growth Factor-beta 1 Gene Polymorphisms with Atherosclerotic Vascular
Disease in Peritoneal Dialysis Patients
|
Seong Cho, M.D.1, Chan-Duck Kim, M.D.2, Hye Myung Ryu, M.D.2 Sun-Hee Park, M.D.2 and Yong-Lim Kim, M.D.2 |
Department of Internal Medicine1 Sungkyunkwan University College of Medicine, Masan, Korea Department of Internal Medicine2 Kyungpook National University School of Medicine, Daegu, Korea |
원저 : 복막투석 환자에서 TGF-β1 유전자 다형성과 동맥경화성 혈관질환 유병율과의 관계 |
조 성1 김찬덕2 류혜명2 박선희2 김용림2 |
성균관대학교 의과대학 마산삼성병원 내과1, 경북대학교 의과대학 내과학교실2 |
|
Abstract |
Purpose : Atherosclerotic vascular disease (AVD) is a leading cause of morbidity and mortality in patients with end-stage renal disease (ESRD) on peritoneal dialysis (PD). Transforming growth factorbeta 1 (TGF-β1) is a multifunctional cytokine that inhibits the atheromatous process. The author studied polymorphisms of the TGF-β1 gene (-509C>T and 869T>C) as genetic susceptibility factors for AVD in PD patients.
Methods : Genotyping was carried out using the LightCycler 480 with melting curve analysis function. Prevalent vascular disease was defined by the presence of ischemic heart disease (IHD), peripheral vascular disease (PVD), cerebrovascular disease (CVD), or congestive heart failure (CHF). The presence of AVD was derived by the presence of any vascular disease (i.e., any degree of IHD/PVD/CVD).
Results : In total, 109 PD patients were recruited (38.7% male, and 28.7% diabetic). The mean age was 49.1±14.1 years, and mean dialysis duration was 61.3±34.1 months. The most frequent genotype at -509C>T was CT (49.5%) and at 869T>C was TC (47.7%). No significant differences were observed in the genotype distributions of the investigated TGF-β1 (CC:CT:TT, 18.5%:55.6%:25.9% vs 26.8%:47.6%:25.6%, χ2=0.246, p=0.884; TT:TC:CC, 18.5%:55.6%:25.9% vs 28.0%:45.1%:26.8%, χ2=1.188, p=0.552) between AVD group and no AVD group.
Conclusion : TGF-β1 gene polymorphisms at both -509C>T and +869T>C were not associated with an increased risk for prevalent vascular diseases. Further studies are required to evaluate the role of TGF-β1 as a candidate gene.
|
Key Words:
TGF-beta 1, Peritoneal dialysis, Genetic polymorphisms, Atherosclerosis |
|